Bioresource Science Course
Applied Biological Chemistry

Yoshihiro Nishida Prof. Ph.D.




arrowadd "" after "@" for an e-mail address

Dr. Yoshihiro NISHIDA received Ph. D. from Tohoku University (Sendai) in 1985 under the guidance of Prof. H. Meguro and Prof. H. Ohrui (Stereochemical studies on sugars and the related natural products). After stayed as a postdoctoral research fellow (JSPS, 1985-1987) at Tohoku University, he became an assistant professor of Nagoya University (Faculty of Engineering, 1996) and then a professor of Chiba University (Faculty of Horticulture, 2007). He is an Alexander von Humboldt Fellow and collaborated with Prof. Hans Paulsen, Prof. Joachim Thiem, and Prof. Volkmar Vill in University of Hamburg. He serves as a science advisor of M. Bio Technology Co. Ltd. (Tokyo) and a regional editor of Journal of Carbohydrate Chemistry (Marcel Dekker Inc.). He received a Young Scientist Award from Japan Society for Bioscience, Biotechnology, and Agrochemistry (1995). His current interest is focused on the molecular design of sugar-based reagents and their practical use for solving the worldwide problem of infection diseases and bio-terrorism.


Most of infectious diseases involving those by Influenza and Bacterial toxins are thought to start from recognition of the host cell-surface oligosaccharides. For instance, Influenza viruses possess adhesion proteins (hemagglutinin) and also the hydrolytic enzymes (neuraminidase) recognizing either a sialyl alpha(2-3)- or an alpha(2-6)-beta-D-galactosyl linkage. Shiga toxins (Stx-1 and Stx-2) binds to alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranosyl linkage (Gb3) neglecting the isomeric alpha(1-3)-linkage (iso-Gb3). Usually, the recognition is highly species-specific like the case of antigen-antibody recognition. This fact means that the cell-surface saccharides can be used as sugar-based drugs against infection events, and this concept is in a central part of scientific attention and efforts (1). Our studies have also been dedicated to these subjects for a decade, targeting Shiga toxins, Influenza viruses, BSE prion proteins, and Mycoplasma, in which we have developed effective synthetic approaches to artificial glycoconjugates based on the concept of carbohydrate modules (2,3), the use of fullerenes as a artificial lipid (4), and the one-pot alpha-glycosylation (5).

1) Reviewed in Y. Nishida, H. Dohi, K. Kobayashi, Trends in Glycosci. Glycobiol. 17, 59-69 (2005).

2) a) K. Sasaki, Y. Nishida, H. Uzawa, K. Kobayashi et al., Angew. Chem. Int. Ed. 41, 4463-4467 (2002).
b) H. Dohi, Y. Nishida, H. Uzawa, K. Kobayashi et al.; Org. Lett., 4, 355-357 (2002).

3) a) Y. Nishida, A. Mizuno, H. Kato, K. Kobayashi et al., Chem. Biodiversity. 1, 1452-1464 (2004).
b) H. Kato, N. Kaneta, Y. Nishida, et. al. Chem. Biodiversity 2, 1232-1241 (2005).

5) (a) Y. Nishida and Y. Shingu et al., Org. Lett., 5, 2377-2380 (2003).
(b) Y. Shingu and Y. Nishida et al., Carbohydrate Res., 340, 2236-2244 (2005).